Approved study title: "Feasibility, acceptability, and safety of creatine monohydrate supplementation for cognitive function and mood in postmenopausal females with dementia risk: a randomised, double-blind, placebo-controlled, feasibility trial."
MENOCOG is investigating the feasibility, acceptability, and safety of creatine monohydrate supplementation in postmenopausal females with dementia risk. We are recruiting participants to take part in a 12-week study.
A brief overview of why this research is being conducted, who may be eligible, and what taking part involves.
Background
Menopause is a natural life stage that may coincide with changes in cognitive function and mood for some women. This feasibility trial explores whether a research programme investigating creatine monohydrate supplementation is practical, acceptable, and safe in this population.
Learn moreEligibility
You may be eligible if you are a postmenopausal female aged 45–65 years with subjective cognitive complaints and one or more recognised risk factors for dementia. Eligibility is confirmed by the research team following your registration of interest.
Check eligibilityInvolvement
The study involves a 12-week supplementation period with either creatine monohydrate or a placebo, cognitive and mood assessments, and safety monitoring. Most components can be completed remotely.
See the timelineA feasibility trial is a preliminary study designed to assess whether a full-scale clinical trial is practical, acceptable to participants, and safe. MENOCOG is not designed to test whether creatine monohydrate has a therapeutic effect on cognition or dementia risk — it is designed to determine whether a larger study is achievable.
Primary outcomes include recruitment rates, protocol adherence, participant retention, and the safety profile of the supplementation in this population.
Cognitive and mood measures are included as secondary and exploratory outcomes to inform the design of future research, not to establish efficacy.
This study is not claiming that:
✗ Creatine prevents or treats dementia
✗ Creatine improves cognitive function
✗ Creatine treats menopause symptoms
✗ Supplementation reduces dementia risk
This study is investigating whether a future, larger trial exploring these questions is feasible, safe, and acceptable to participants.
Registering your interest is not a commitment to participate. The research team will review your enquiry and contact you with further information about eligibility and next steps.
